Amgen (NASDAQ:AMGN) announced Tuesday that it has consummated the purchase from Astellas of 49% of shares of Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen and Astellas established in 2013. AABP, which is now a wholly-owned Amgen affiliate in Japan renamed Amgen K.K., has enabled Amgen to build a strong presence in Japan as it advances treatments for serious illnesses. “With roughly one-quarter of its population 65 or older, Japan will require ever more innovative medicines to treat diseases associated with the aging process,” said Robert A. Bradway, chairman and chief executive officer of Amgen. “Our current and emerging portfolio of medicines matches up well with the needs of patients in Japan.”
Read the full article: Amgen Establishes Wholly-Owned Affiliate in Japan //
Source: https://www.prnewswire.com/news-releases/amgen-establishes-wholly-owned-affiliate-in-japan-301033016.html